Teng Jin Ong

Suggest Changes
Learn More
PURPOSE This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer(More)
INTRODUCTION Sorafenib monotherapy has shown benefits in phase II trials as third-/fourth-line treatment in patients with non-small-cell lung cancer (NSCLC). METHODS The phase III, multinational,(More)
generation sequencing (NGS) analysis was also performed on these plasma samples. Methods: Agreement (positive and negative) between the cobas tissue test and the cobas plasma test, for detection of(More)